

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss however arising from or in reliance upon the whole or any part of the contents of this announcement.



Suzhou Basecare Medical Corporation Limited

蘇州貝康醫療股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2170)

VOLUNTARY ANNOUNCEMENT SHARE REPURCHASE UNDER THE REPURCHASE MANDATE

This announcement is made by Suzhou Basecare Medical Corporation Limited (the “**Company**”) on a voluntary basis.

Pursuant to a resolution passed by the shareholders of the Company (the “**Shareholders**”) at the 2025 annual general meeting of the Company held on June 4, 2026, the board (the “**Board**”) of directors (the “**Directors**”) of the Company has been granted a general unconditional mandate (the “**Repurchase Mandate**”) to repurchase H shares of the Company (the “**H Shares**”) not exceeding 10% of the total number of H Shares in issue as at June 4, 2026 (i.e. 8,271,383 H Shares).

The Board is pleased to announce that it intends to exercise its power under the Repurchase Mandate and that the Company will, from time to time, repurchase H Shares on the open market for an amount of not more than RMB5 million, subject to market conditions and the terms of the Repurchase Mandate (the “**Share Repurchase Plan**”). The Repurchase Mandate will expire at the earliest of: (i) the conclusion of the next annual general meeting of the Company; (ii) the expiration of the period within which the next annual general meeting of the Company is required to be held by the articles of association of the Company (as amended from time to time, the “**Articles of Association**”) or by any applicable laws; and (iii) the date on which the authority given under the relevant resolution approving the Repurchase Mandate is revoked or varied by a requisite resolution of the Shareholders in accordance with the then effective Articles of Association.

The Share Repurchase Plan is based on the confidence of the management team, the Company’s current operational growth outlook and financial position while acknowledging recent market conditions. The Company intends to fund the Share Repurchase Plan from its own financial resources and not from the proceeds of the listing of the H Shares on The Stock Exchange of Hong Kong Limited. The Board is of the view that the current trading price of the H Shares undervalues the Company’s intrinsic value and business outlook, and the Share Repurchase Plan will enhance Shareholders’ value.

The Share Repurchase Plan demonstrates the Board's confidence in the long-term growth of the Company and will only be conducted under circumstances which the Board considers to be appropriate and in the interest of the Company and the Shareholders as a whole. The Company will exercise the Repurchase Mandate in compliance with the Articles of Association, the Listing Rules, the Codes on Takeovers and Mergers and Share Buy-backs and all applicable laws and regulations to which the Company is subject to.

Shareholders and potential investors of the Company should note that the exercise of the Repurchase Mandate by the Company will be subject to market conditions and will be at the Board's absolute discretion. There is no assurance as to the timing, quantity or price of any repurchase or whether the Company will make any repurchase at all.

Shareholders and potential investors of the Company should therefore exercise caution when dealing in the securities of the Company.

By order of the Board
Suzhou Basecare Medical Corporation Limited
Dr. Liang Bo
Chairman and General Manager

Suzhou, PRC, October 9, 2026

As at the date of this announcement, the Board comprises Dr. LIANG Bo, Mr. KONG Lingyin and Ms. JIANG Junchao as executive Directors; Mr. ZHAO Ye and Mr. WANG Weipeng as non-executive Directors; and Dr. KANG Xixiong, Mr. LAM Siu Wing and Dr. YEUNG Shu Biu William as independent non-executive Directors.